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TAR DNA-binding protein 43 (TDP-43) is the major component of the ubiquitin-positive
protein aggregates seen in the majority of frontotemporal lobar degeneration and
amyotrophic lateral sclerosis cases. TDP-43 belongs to the heterogeneous nuclear
ribonucleoprotein (hnRNP) family that is involved in the regulation of RNA transcription,
splicing, transport and translation. There are a great many hnRNPs, which often have
overlapping functions and act cooperatively in RNA processing. Here we demonstrate
that another hnRNP family member, hnRNP E2, shows a striking accumulation within
dystrophic neurites and cytoplasmic inclusions in the frontal cortex and hippocampus of
a subset of FTLD-TDP cases belonging to pathological subtypes A and C, where hnRNP
E2 was found to co-localize with 87% of TDP-43 immunopositive inclusions. hnRNP
E2-positive inclusions were not seen in FTLD-TDP cases with the C9orf72 expansion
or in any other neurodegenerative disorders examined. This interaction with TDP-43 in
specific FTLD subtypes suggests different underlying neurodegenerative pathways.
Keywords: FTLD, ALS, TDP-43, hnRNP, hnRNP E2
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative disorders
predominantly affecting the frontal and temporal lobes. The group is clinically, pathologically
and genetically heterogeneous. Typically, patients initially present with behavioral dysfunction
and changes in personal and social conduct (behavioral variant) or with disorders of speech and
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language (semantic dementia and progressive non-fluent
aphasia). FTLD can occur alone or, as seen in approximately
15% of cases, accompanied by amyotrophic lateral
sclerosis (ALS) with progressive upper and lower motor
neuron degeneration.
Approximately 30–50% of FTLD cases are familial with an
autosomal dominant pattern of inheritance. Reported mutations
includeMAPT,GRN,VCP and the GGGGCC repeat expansion in
the C9orf72 gene (Watts et al., 2004; Baker et al., 2006; DeJesus-
Hernandez et al., 2011).
Pathologically, FTLD cases exhibit intraneuronal (and in some
cases glial) inclusions formed of abnormally aggregated proteins.
Cases can be classified according to the type of hallmark protein
accumulated in the neuronal inclusions, with most cases showing
inclusions positive for either tau (FTLD-tau) or TDP-43 (FTLD-
TDP) and, less frequently, FUS (FTLD-FUS).
Since 2011, a harmonized classification has been used in
FTLD-TDP cases based on the morphology and neuroanatomical
distribution of inclusions (Mackenzie et al., 2011). Briefly, FTLD-
TDP type A is characterized by crescentic or oval neuronal
cytoplasmic inclusions (NCI) and numerous short dystrophic
neurites (DN), primarily in layer 2 of the neocortex. Lentiform
neuronal intranuclear inclusions (NII) can sometimes be seen,
however, they are not a consistent feature of this subtype.
Type B is characterized by a moderate number of NCI in
all cortical layers and very few DN. Type C have numerous
elongated DN in the upper cortical layers but very few NCI.
Type D FTLD-TDP refers to the pathology associated with VCP
mutations and is characterized by frequent lentiform NII and
numerous short DN. The pathological subtypes of FTLD-TDP
cases have some correlation to the clinical phenotypes, subtype
A being associated with behavioral variant of frontotemporal
dementia (bvFTD) or progressive non-fluent aphasia (PFNA),
subtype B with bvFTD and often combined with ALS and
subtype C with semantic dementia. Subtype D is often
associated with Paget’s disease of bone and hereditary inclusion
body myopathy
Normally TDP-43 is predominantly localized to the
nucleus, however, it is continuously shuttling between the
nucleus and the cytoplasm (Ayala et al., 2008; Prpar Mihevc
et al., 2017). It is capable of binding to nucleic acids, with
involvement in RNA splicing, stability, transcription and
translation (Da Cruz and Cleveland, 2011; Tollervey et al.,
2011; Buratti and Baralle, 2012). TDP-43 is a member
of the heterogeneous ribonucleoprotein (hnRNP) family
and interacts with a number of other members, mainly
through its C-terminal tail (Romano et al., 2014). Mutations
in TDP-43 have been associated with ALS, but not FTLD
(Sreedharan et al., 2008).
Other hnRNPs have previously been reported to be associated
with pathology in FTLD-TDP. hnRNP A3 was identified as a
component of some of the p62-positive and TDP-43-negative
hippocampal inclusions seen in a subset of FTLD/ALS cases with
the C9orf72 expansion; it was also shown to be a component
of “RNA foci” and it has been suggested that it binds to the
GGGGCC repeats in C9orf72 transcripts (Mori et al., 2013);
however, its pathogenic role has not yet been determined.
In addition, the recent implication of hnRNP A2/B1 and
hnRNP A1 in ALS and multisystem proteinopathy supports
the hypothesis of a physical and functional interaction between
TDP-43 and other hnRNPs (Calini et al., 2013; Kim et al.,
2013; Romano et al., 2014). The relative expression of a specific
protein within the TDP-43 interaction network may have a
significant impact on the function of TDP-43, either through
direct interaction or independently by acting on the same
cellular targets (Hanson et al., 2010; Buratti and Baralle, 2012;
Mohagheghi et al., 2016).
hnRNP E2 is an RNA-binding protein that belongs to the
hnRNP K family of proteins. They are characterized by triple
K Homology (KH) domains that can interact independently
with target RNA sequences, which allows this protein family
to potentially form highly complex-specific RNA interactions.
hnRNP E2 has been reported to incorporate into stress granules
alongside TDP-43 (Fujimura et al., 2008; Liu-Yesucevitz et al.,
2010) and in a recent pathological study hnRNP E2 was
shown to colocalise with TDP-43 inclusions in FTLD cases
which presented with the semantic dementia clinical phenotype
(Davidson et al., 2017).
Here we examined the expression of hnRNP E2 in a large
cohort of cases, including a FTLD-TDP cohort comprising
cases from all 4 pathological subtypes, cases with and without
the C9orf72 expansion, controls, and a number of other
neurodegenerative diseases.
MATERIALS AND METHODS
Case Selection and Tissue Preparation
Post-mortem brain tissue samples in 10% formalin-fixed paraffin
embedded blocks were obtained from the MRC London
Neurodegenerative Diseases Brain Bank at the Institute of
Psychiatry, Psychology and Neuroscience, King’s College London.
Consent for autopsy, neuropathological assessment and research
was obtained for all cases and the study was carried out
under the ethical approval of the tissue bank. Block taking
and neuropathological assessment was performed according to
standard criteria.
Tissue samples were selected from a total of 108 cases. 30
cases of FTLD-TDP without the C9orf72 expansion (FTLD-
TDP) were examined (comprising 15 classified as pathological
subtype A, four subtype B, nine subtype C, one subtype D
case and one which could not be definitively classified due
to atypical inclusions). Additionally, 24 FTLD-TDP cases with
C9orf72 expansion were investigated (FTLD-TDP-C9orf72) (of
which three were identified as subtype A, 16 as subtype B, and
five which could not be definitively subtyped).
To investigate the specificity of hnRNP E2 to FTLD-TDP,
seven FTLD with tau aggregates (FTLD-Tau), 14 sporadic ALS
(sALS), three ALS with SOD1 mutations (ALS-SOD), three ALS
with FUS mutations (ALS-FUS) and one ALS with a TARDBP
mutation were examined.
To determine the specificity of hnRNP E2 to FTLD, seven
Alzheimer’s disease, two Dementia with Lewy bodies (DLB),
one argyrophilic grain disease (AGD), one spinocerebellar ataxia
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(SCA) and one Huntington’s disease case were examined.
Fourteen healthy controls without a history of neurological
problems or psychiatric disorders and without any significant
pathology (matched for gender, age and post-mortem delay) were
also investigated (see Table 1 for details).
In each case frontal and temporal lobe (containing the
hippocampus) were examined. In some cases (where available)
the spinal cord was also studied.
Immunohistochemistry
Seven micrometer thick, formalin fixed, paraffin embedded
sections were cut from the middle frontal gyrus, hippocampus
and, in some cases, the spinal cord. Immunohistochemistry
was conducted as per previously published protocols (Maekawa
et al., 2009). In brief, sections were deparaffinised in xylene
and endogenous peroxidase was blocked by immersion in
2.5% H2O2 in methanol. Antigen retrieval was enhanced
using an extended microwave citrate buffer treatment. After
blocking in normal swine serum (DAKO, Cambridgeshire,
United Kingdom) 1:10 for 20 min, hnRNP E2 antibody
(hnRNP E2-23G, sc-101136, Santa Cruz) was applied at 1:500
overnight at 4◦C. Following washes, the sections were incubated
with biotinylated secondary antibody (DAKO), followed by
avidin:biotinylated enzyme complex (Vectastain Elite ABC kit,
Vector Laboratories, Peterborough, United Kingdom). The
sections were then incubated for 10–15 min with 0.5 mg/mL 3,3′-
diaminobenzidine chromogen (Sigma-Aldrich Company Ltd.,
Dorset, United Kingdom) in Tris-buffered saline (pH 7.6)
containing 0.05% H2O2. The sections were counterstained with
Harris’ haematoxylin and immunostaining analyzed using a
Leica microscope.
Double Immunofluorescence
To investigate co-localisation of hnRNP E2 with ubiquitin
and TDP-43, double immunofluorescence was carried out
on a subset of the FTLD-TDP cases. Seven micrometer
sections cut from formalin-fixed paraffin-embedded blocks were
deparaffinised in xylene and dehydrated in 99% industrial
methylated spirit. Sections were pre-treated with microwave
heating in citrate buffer and normal serum blocking was
performed using normal goat serum (1:10 for 45 min). Sections
were incubated overnight at 4◦C with hnRNP E2 (hnRNP
E2-23G: sc-101136, Santa Cruz) at 1:200 with either TDP-43
(Proteintech, 10782-2-AP) at 1:250 or anti-ubiquitin (Dako,
Z045801) at 1:100.
After washes, sections were incubated with AlexaFluor
secondary antibodies (goat anti-mouse 488 and goat anti-
rabbit 568, Invitrogen, Paisley, United Kingdom). Sections
were treated with Sudan Black for 10 min to quench
autofluorescence. Following numerous washes in phosphate
buffered saline, sections were mounted with Vectashield hard
set media containing DAPI. Sections were visualized using
a fluorescent microscope (Zeiss Axiovert S 100, Gottingen,
Germany) and images captured using ImagePro Express
(v6) (Meyer Instruments, Houston, TX, United States).
Sections were also examined using confocal microscopy (Leica
confocal SP system) and captured images analyzed using
ImageJ 1.47v software.
Statistical Analysis of hnRNP-E2
Pathology and Demographic Data
A Chi-square test of independence was performed to examine the
relationship between gender, age at death, post-mortem delay and
fixation time with presence of hnRNP E2 pathology.
RESULTS
Immunohistochemistry for hnRNP E2 showed striking
inclusions in 17 FTLD-TDP cases, specifically those with
subtype A and C pathology (see Table 1). The inclusions showed
a similar pattern to that of the TDP-43 pathology. In subtype
A FTLD-TDP cases six out of 15 cases showed hnRNP E2
inclusions in the frontal cortex with two of these also showing
inclusions in the hippocampus and in the spinal cord. Within
the frontal cortex hnRNP E2 inclusions were predominant
in the superficial layers, mainly in layer 2 of the neocortex,
with numerous perinuclear cytoplasmic neuronal inclusions and
frequent dystrophic neurites (Figure 1B). Similar inclusions were
detected within the hippocampus granular cells (Figure 1C). In
the spinal cord, sparse inclusions were detected in the anterior
horn of the thoracic spinal cord in the two cases (Figure 1D).
All nine subtype C cases showed hnRNP E2 inclusions in the
frontal cortex; long dystrophic neurites were predominantly
detected in the superficial layers of the frontal cortex (Figure 1E)
and in the hippocampus (Figure 1F). In all nine cases round
intracellular inclusions were also detected in the granular
cells of dentate fascia (Figure 1G) and in one case inclusions
were seen in the spinal cord. hnRNP E2-positive inclusions
were seen in both the frontal cortex and the spinal cord of an
additional FTLD-TDP case that, due to atypical p62 positive,
TDP negative intranuclear inclusions, could not be definitively
classified into a sub-group. No hnRNP E2 positive inclusions
were seen in either the frontal cortex or hippocampus of the
FTLD-TDP subtype D case (Figure 1H). Inclusions were seen
in just one of the FTLD-TDP C9orf72 expansion positive cases
(classified as a subtype B). Within control cases, the hnRNP
E2 immunohistochemistry showed weak diffuse staining in the
cytoplasm and stronger nuclear staining (Figure 1A). No hnRNP
E2 aggregates were seen in the brain or spinal cord in any disease
other than FTLD-TDP, with staining appearing similar to the
control cases.
Co-localisation of TDP-43 and hnRNP E2
Double immunofluorescence revealed a strong relationship
between TDP-43 and hnRNP E2, in both the frontal cortex
(Figures 2A1–A3) and hippocampus (Figures 2B1–B3) with
87% of the TDP-43-positive inclusions being found to co-
localize with hnRNP E2 (a total of 583 TDP-43 positive
inclusions and 507 hnRNP E2 positive inclusions were counted
in three FTLD-TDP type A cases and four FTLD-TDP type
C cases). Higher magnification images of individual cells
were obtained using a confocal microscope, which showed
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TABLE 1 | List of cases used in the study, showing demographic details and hnRNP E2 immunohistochemistry positivity.
MRC ID Diagnosis TDP-Subtype Sex Age at death PMD Fixation time hnRNP E2 positivity
Frontal H/C SC
BBN_1085 FTLD-TDP A M 87 41 12 N N N/A
BBN_15298 FTLD-TDP (?ALS) A M 69 42 5 Y Y Y
BBN_10599 FTLD-TDP A F 79 56 6 Y N N/A
BBN_4568 FTLD-TDP A M 59 36 4 Y Y Y
BBN_15299 FTLD-TDP A M 88 31 8 Y N N/A
BBN_15306 FTLD-TDP A M 71 14 8 N N N
BBN_10245 FTLD-TDP A M 87 31 10 Y N N
BBN_9863 FTLD-TDP A M 73 25 8 N N N/A
BBN_15281 FTLD-TDP A F 67 15 7 N N N/A
BBN_19697 FTLD-TDP A F 78 72 8 N N N/A
BBN_15302 FTLD-TDP A M 81 11 24 N N N/A
BBN_16282 FTLD-TDP A M 78 >100 4 N N N/A
BBN_15292 FTLD-TDP A F 56 35 10 Y N N/A
BBN_15287 FTLD-TDP A F 74 70 8 N N N/A
BBN_15283 FTLD-TDP A M 70 57 22 N N N/A
BBN_9950 FTLD-TDP B M 72 38 12 N N N/A
BBN_4590 FTLD-TDP B F 73 54 8 N N N
BBN_15289 FTLD-TDP B M 68 46 4 N N N
BBN_11067 FTLD-TDP B M 81 31 8 N N N/A
BBN_15303 FTLD-TDP C M 69 6 12 Y Y N
BBN_15286 FTLD-TDP C M 68 120 7 Y Y N
BBN_15200 FTLD-TDP C M 69 16 11 Y Y N
BBN_15294 FTLD-TDP C F 85 24 11 Y Y N/A
BBN_15304 FTLD-TDP C M 80 45 20 Y Y N
BBN_15295 FTLD-TDP C M 82 14 16 Y Y Y
BBN_15297 FTLD-TDP C M 78 24 12 Y Y N/A
BBN_15288 FTLD-TDP C M 80 7 12 Y Y N/A
BBN_15290 FTLD-TDP C M 66 54 8 Y Y N
N/A FTLD-TDP D M 61 3 14 N N N
BBN_4249 FTLD-TDP NC M 86 45 6 Y N N
BBN_15300 FTLD-ALS C9orf72 A M 79 35 5 N N N/A
BBN_15291 FTLD-ALS C9orf72 A M 56 19 11 N N N/A
BBN_16438 FTLD-ALS C9orf72 A F 58 12 61 N N N/A
BBN_15279 FTLD-C9orf72 B F 57 16 18 N N N
BBN_6230 FTLD-ALS C9orf72 B M 71 44 17 Y N Y
BBN_15296 FTLD-C9orf72 B F 70 16 12 N N N
BBN_16615 FTLD-ALS C9orf72 B F 64 44 4 N N N/A
BBN_15713 FTLD-ALS C9orf72 B M 57 23 35 N N N/A
BBN_6252 FTLD-ALS C9orf72 B F 43 69 14 N N N/A
BBN_6254 FTLD-ALS C9orf72 B M 53 82 10 N N N/A
BBN_16304 FTLD-ALS C9orf72 B M 59 46 10 N N N/A
BBN_16651 FTLD-ALS C9orf72 B M 51 64 7 N N N/A
BBN_16458 FTLD-ALS C9orf72 B M 70 40 8 N N N/A
BBN_6227 FTLD-ALS C9orf72 B M 55 76 31 N N N/A
BBN_6198 FTLD-ALS C9orf72 B M 58 11 15 N N N/A
BBN_10306 FTLD-ALS C9orf72 B M 64 68 11 N N N/A
BBN_16969 FTLD-ALS C9orf72 B F 57 12 12 N N N/A
BBN_4253 FTLD-ALS C9orf72 B F 59 21 10 N N N/A
BBN_6251 FTLD-ALS C9orf72 B M 62 74 14 N N N/A
(Continued)
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TABLE 1 | Continued
MRC ID Diagnosis TDP-Subtype Sex Age at death PMD Fixation time hnRNP E2 positivity
Frontal H/C SC
BBN_16380 FTLD-ALS C9orf72 NC F 59 35 17 N N N/A
BBN_16223 FTLD-ALS C9orf72 NC M 55 19 17 N N N/A
BBN_6242 FTLD-ALS C9orf72 NC F 39 70 18 N N N/A
BBN_6232 FTLD-ALS C9orf72 NC M 70 38 12 N N N/A
BBN_15641 FTLD-ALS C9orf72 NC F 70 60 37 N N N/A
BBN_15268 FTLD-Tau F 58 31 13 N N N/A
BBN_15269 FTLD-Tau M 67 35 9 N N N/A
BBN_15284 FTLD-Tau F 62 31 9 N N N/A
BBN_10282 FTLD-Tau M 72 6 19 N N N/A
BBN_10281 FTLD-Tau M 61 23 21 N N N/A
BBN_15776 FTLD-Tau M 66 17 3 N N N/A
BBN_15285 FTLD-Tau M 67 17 7 N N N/A
BBN_6244 sALS M 55 33 22 N N N/A
BBN_6187 sALS M 70 73 75 N N N/A
BBN_10272 sALS M 87 70 22 N N N/A
BBN_6248 sALS M 66 38 8 N N N/A
BBN_15715 sALS M 74 34 40 N N N/A
BBN_6219 sALS M 49 33 33 N N N/A
BBN_6267 sALS M 68 5 18 N N N/A
BBN_6257 sALS F 69 64 14 N N N/A
BBN_6243 sALS M 67 70 11 N N N/A
BBN_6217 sALS F 56 39 56 N N N/A
BBN_6268 sALS M 78 2 18 N N N/A
BBN_6280 sALS M 75 38 9 N N N/A
BBN_10285 sALS M 42 41 23 N N N/A
BBN_16384 sALS F 57 15 23 N N N/A
BBN_16392 ALS-SOD F 61 14 21 N N N/A
BBN_10276 ALS-SOD M 47 14 18 N N N/A
BBN_16553 ALS-SOD F 46 5 14 N N N/A
BBN_6245 ALS-FUS F 35 13 5 N N N/A
BBN_6189 ALS-FUS F 35 24 39 N N N/A
BBN_10244 ALS-FUS F 23 37 12 N N N/A
BBN_19995 ALS-TARDBP M 57 48 9 N N N/A
BBN_9933 Alzheimer’s Disease F 98 25 9 N N N/A
BBN_9934 Alzheimer’s Disease M 70 60 19 N N N/A
BBN_4182 Alzheimer’s Disease F 81 23 18 N N N/A
BBN_4183 Alzheimer’s Disease F 79 40 8 N N N/A
BBN_9801 Alzheimer’s Disease F 90 23 20 N N N/A
BBN_9927 Alzheimer’s Disease F 90 35 18 N N N/A
BBN_9930 Alzheimer’s Disease M 101 48 12 N N N/A
BBN_16337 DLB M 85 30 18 N N N/A
BBN_10290 DLB M 78 41 25 N N N/A
BBN_2924 Agyrophilic Grain Disease M 82 20 8 N N N/A
BBN_15766 SCA F 74 33 53 N N N/A
BBN_11070 Huntington’s disease M 65 36 8 N N N/A
BBN_15777 Control F 87 22 150 N N N/A
BBN_15753 Control M 64 71 53 N N N/A
BBN_16291 Control M 81 18 17 N N N/A
(Continued)
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TABLE 1 | Continued
MRC ID Diagnosis TDP-Subtype Sex Age at death PMD Fixation time hnRNP E2 positivity
Frontal H/C SC
BBN_16242 Control F 90 50 19 N N N/A
BBN_15621 Control M 61 53 14 N N N/A
BBN_16429 Control M 68 53 4 N N N/A
BBN_16280 Control M 78 24 8 N N N/A
BBN_16277 Control M 54 30 8 N N N/A
BBN_15791 Control M 95 44 20 N N N/A
BBN_15790 Control M 40 40 25 N N N/A
BBN_16256 Control M 62 80 18 N N N/A
BBN_16251 Control M 66 52 7 N N N/A
BBN_22991 Control F 73 27 6 N N N/A
BBN_16525 Control F 77 29 14 N N N/A
PMD (post-mortem delay), H/C (hippocampus), SC (spinal cord) ?ALS (sparse pathology seen in cord but no clinical symptoms reported), sALS (sporadic ALS), DLB
(Dementia with Lewy bodies), SCA (Spinocerebellar ataxia), NC (non-classifiable), N/A (not available). Y (hnRNP-E2 positive aggregates).
FIGURE 1 | Immunohistochemistry for hnRNP E2. (A) Weak cytoplasmic staining and stronger nuclear staining is seen in the frontal cortex of a control case (case ID
BBN_16256). (B–D) Sections from a FTLD-TDP subtype A case showed numerous perinuclear cytoplasmic neuronal inclusions and frequent dystrophic neurites,
mainly in layer 2 of the frontal cortex (B). Similar cytoplasmic inclusions were detected in hippocampal neurons (C) and sparsely in the anterior horn of the spinal
cord (D) (case ID BBN_15298). (E–G) In FTLD-TDP subtype C there were frequent long dystrophic neurites in the superficial layers of the frontal cortex (E) and in the
hippocampus (F). Within the granular cells of the dentate fascia round intracellular inclusions were seen (G) (case ID BBN_15303). (H) No inclusions were seen in the
frontal cortex of the subtype D case (H). Scale bar represents 20 µm in panels (A,B,E); 80 µm in panels (C,D,G); 100 µm in panel (F,H).
the complete co-localisation of both TDP-43 and hnRNP
E2 in the perinuclear inclusions and dystrophic neurites,
respectively (Figures 2C1–C3). Images were also obtained from
a type C FTLD-TDP case where mainly TDP-43 dystrophic
neurites are detected in the frontal cortex, again, complete
co-localisation of hnRNP E2 with TDP-43 was detected
(Figures 2D1–D3). Interestingly the C9orf72 positive case
showed little co-localisation between hnRNP E2 and TDP-43
(image not shown).
Co-localisation of Ubiquitin and
hnRNP-E2
hnRNP E2 was also present in 70% of the ubiquitin-
positive inclusions in the frontal cortex (Figures 3A1–A3)
and hippocampus (Figures 3B1–B3) of the same cases
(with a total of 810 ubiquitin positive inclusions and
571 hnRNP-E2 positive inclusions being counted from
three FTLD-TDP type A cases and four FTLD-TDP
type C cases). High resolution images of the hnRNP
E2/ubiquitin inclusions appear to show hnRNP E2 is partially
ubiquitinated (Figures 3C1–C3,D1–D3).
Effects of Gender, Age, PMD and
Fixation Time
hnRNP E2 pathology was found to be independent of both gender
and age. There was also no significant effect of PMD or fixation
time on the presence of hnRNP E2 pathology in the FTLD-TDP
cases (Table 2).
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FIGURE 2 | Co-localisation of TDP-43 and hnRNP E2. Double-labeling immunofluorescence shows inclusions positive for TDP-43 (red) (A1) and hnRNP E2 (green)
(A2) in the frontal cortex of a subtype A case, the merged image (A3) shows numerous areas of co-localisation (case ID BBN_15298). Co-localisation is also seen in
the hippocampus, panels (B1–B3) show a subtype A case (case ID 482 BBN_4568). Higher magnification images demonstrate the complete co-localisation of the
TDP-43 and hnRNP E2 in a perinuclear inclusion from the subtype A case (C1–C3) and along a dystrophic neurite in a subtype C case (D1–D3) (case ID
BBN_15303). Scale bar represents 100 µm in panels (A1–A3,B1–B3), 25 µm in panels (C1–C3,D1–D3).
DISCUSSION
Since its identification as the major component of the protein
aggregates in the majority of ALS and FTLD cases, TDP-
43 has been subject to much investigation. However, its
mechanistic role in neuronal degeneration has not yet been
fully characterized. Identifying proteins that interact with TDP-
43 would represent a major step forward in understanding the
pathological mechanism and pathways.
In this study we report that immunohistochemistry for
hnRNP E2 revealed prominent perinuclear cytoplasmic
inclusions and dystrophic neurites in FTLD-TDP patient tissue –
specifically in those classified as pathological subtypes A (6/15)
and C (9/9). Positive inclusions were also seen in an additional
FTLD-TDP case which was unable to be exactly classified, as
well as in just a single C9orf72 expansion positive case [classed
as subtype B – although it should be noted that the classification
of C9orf72 cases can sometimes be difficult (Mackenzie and
Neumann, 2017)]. Inclusions were not seen in subtype B or D
FTLD-TDP or in the majority of C9orf72 expansion-positive
cases, despite the presence of TDP-43 inclusions. This adds to the
increasing evidence for differences in the underlying mechanisms
driving TDP-43 aggregation in different subtypes of FTLD-TDP.
It has been proposed that TDP-43 may not be the driving
force behind the neurodegeneration seen in C9orf72 expansion
cases (Leko et al., 2019) although this remains controversial
(Mackenzie et al., 2015). No inclusions were seen in control cases
or in any other neurodegenerative condition investigated.
Further insight into the functions of hnRNP E2 within
the nervous system could provide an explanation for the co-
localisation of hnRNP E2 with TDP-43 in the inclusions. Recent
evidence suggests one explanation could be the role of hnRNP
E2 in the regulation of apoptosis. Evidence of neuronal apoptosis
has been reported in ALS and FTLD-TDP cases, with elevated
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FIGURE 3 | Co-localisation of ubiquitin and hnRNP E2. Double-labeling immunofluorescence of Ubiquitin (red) and hnRNP E2 (green) shows high levels of
co-localisation within the frontal cortex (A1–A3) and hippocampus (B1–B3) of a subtype A case (case ID BBN_4568). Strong co-localisation can be seen within the
inclusions in a subtype A case (C1–C3) (case ID BBN_15298). In a subtype C case, some inclusions show only ubiquitin positivity (D1) and some only hnRNP-E2
positivity (D2). Within inclusions showing both proteins, the co-localisation is not absolute (D3) (case ID BBN_15303). Scale bar represents 80 µm in panel (A1–A3),
50 µm in panel (B1–B3), 20 µm in panels (C1–C3,D1–D3).
levels of activated caspase-3 seen in the spinal cord and brain
(Martin, 1999; Su et al., 2000) and caspase-3 being identified
as the protease responsible for TDP-43 fragmentation (Zhang
et al., 2007). Interestingly, caspase-3 downregulates TDP-43 in
glioma cells (Nan et al., 2014). Previous studies have linked
hnRNP E2 to caspase-3 activation; hnRNP E2 is upregulated
in human glioma tissue, while hnRNP E2 knockdown inhibited
glioma growth through the induction of caspase-3-mediated
apoptosis and the inhibition of cell-cycle progression (Han et al.,
2013). Additionally, it has been reported that the overexpression
of hnRNP E2 induces apoptosis in human oral cancer cells
(Roychoudhury et al., 2007). Following spinal cord injury, both
hnRNP E2 and caspase-3 were upregulated in neurons (Mao
et al., 2016) and knockdown of hnRNP E2 decreased the
expression of caspase-3 in primary neuronal cultures. However,
the levels of cyclin D1 did not change after hnRNP E2
knockdown, which suggested that hnRNP E2-induced neuronal
apoptosis is independent of cell cycle activation (Mao et al.,
2016). The detailed mechanism of how hnRNP E2 may modulate
caspase-3 activity and apoptosis has not yet been clarified but it
is possible that this mechanism may mediate TDP-43 aggregation
in some FTLD-TDP cases.
TABLE 2 | No significant effect of gender, age, post-mortem delay or fixation time
was seen on hnRNP E2 positivity in FTLD-TDP cases using a Pearson’s
Chi-squared test (for gender) or Welch Two Sample t-test (for age, post-mortem
delay and fixation time) df = degrees of freedom.
Variable Test Df p-value
Gender X-squared = 0.4026 1 0.5257
Age t = −0.3908 26.293 0.6991
Post-mortem delay t = 0.5136 26.736 0.6118
Fixation time t = 0.3276 22.793 0.7462
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A further possible explanation for the co-localisation of
hnRNP E2 and TDP-43 in the FTLD-TDP brain is their
role in the stress response. It has been shown that TDP-43
and hnRNP E2 are both recruited into stress granules under
stress conditions (Fujimura et al., 2008; Monahan et al., 2016).
Following oxidative stress, endogenous TDP-43 and hnRNP E2
colocalised within stress granules as well as with the stress
granule marker PABP1, an effect that was greatly enhanced
by the sequential addition of an osmotic challenge. hnRNP E2
has been identified as a facilitator of internal ribosome entry
site-mediated translation and to have an important role in
remodeling mRNAs in the stress granules and in transferring
specific mRNAs from stress granules to P-bodies for degradation
(Fujimura et al., 2008, 2009).
Another possible link could be established through
microRNAs (miRNA). Nuclear and cytoplasmic TDP-43
were identified as modulators of miRNA maturation and, by
facilitating miRNA production, to be essential for neuronal
outgrowth (Kawahara and Mieda-Sato, 2012). Interestingly,
hnRNP E2 expression was found to be regulated by miRNA-214;
however, the regulatory pathway still needs to be determined
(Tang et al., 2015).
Both TDP-43 and hnRNP E2 are present alongside ubiquitin
in FTLD-TDP cases, thus, it is possible that ubiquitin could act
as the link between TDP-43 and hnRNP E2. Scotter et al. (2014)
suggested that an impaired ubiquitin proteasome system (UPS)
contributes to elevated TDP-43 levels. The cascade of ubiquitin-
mediated protein degradation involves the stepwise action of
three enzymes, namely the ubiquitin-activating enzyme (E1),
the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase
enzyme (E3), which provide substrate specificity. E3 ubiquitin
ligase recruits the ubiquitin-loaded conjugating enzyme E2,
recognizes a protein substrate and either directly catalyzes or
assists with the transfer of ubiquitin from E2 to the protein
substrate (Hershko and Ciechanover, 1998). hnRNP E2 was
identified as an adapter between the ubiquitin ligase E3 and
the mitochondrial antiviral-signaling protein (MAVS) in cellular
studies (You et al., 2009). The overexpression of hnRNP E2
led to the degradation of MAVS and abolished the cellular
response to viral infection, while the knockdown of hnRNP
E2 had the opposite effect. hnRNP E2 is not a ligase enzyme;
however, it performs a ligase-enzyme-adapting activity, which
recruits the conjugating enzyme to its substrate (You et al.,
2009). Moreover, a ubiquitin ligase complex has been recently
identified that is involved in TDP-43 degradation (Uchida
et al., 2016). The ligase complex consists of the von Hippel-
Lindau protein (VHL) and the cullin-2 (CUL2) RING, which
belongs to the hydrophobic family of proteins that provides a
temporary complex for ubiquitin ligase E3. VHL preferential
binds to the RRM2 of misfolded TDP-43. Interestingly, when
VHL is overloaded in the cytoplasm, it tends to stabilize
and aggregate with TDP-43. VHL was detected in TDP-43
inclusions in spinal cord motor neurons of ALS patients,
suggesting that the imbalance between VHL and CUL2 is the
key to TDP-43 aggregation and highlighted the CUL2 E3 ligase
as a potential therapeutic target for TDP-43 proteinopathies
(Uchida et al., 2016). Determining whether hnRNP E2 could
be a component or an adaptor of this ligase complex requires
further investigation.
Our work corroborates the findings of a recent study by
Davidson et al. (2017), where hnRNP E2 inclusions were reported
in a subset of FTLD-TDP subtype C only. The authors suggested
that long-term storage of tissue in formalin might have been
the cause of variations in hnRNP E2 staining among the FTLD-
TDP type C group. Our study showed inclusions in all type
C cases examined (9/9) as well as a proportion of type A
(6/16). Statistical analysis did not find any significant effect of
fixation time on presence of hnRNP E2 staining, nor was there
any relationship between gender, age or post-mortem delay in
the FTLD-TDP cases.
Our findings highlight the importance of characterizing the
protein composition of aggregates in order to understand the
underlying pathological mechanisms and suggest that the co-
localisation of hnRNP E2 with TDP-43 in inclusions may have
implications in the pathogenesis of a subset of FTLD-TDP
cases - which could even be considered as a subtype in future
classifications of FTLD-TDP-43 proteinopathies.
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